Future Founders In Life Sciences

Register Here and We’ll Send You the Zoom Link.

The Future Founders in Life Sciences Series is a free lecture series for those in life sciences, interested in starting their own company – our goal is to inspire you to just do it!

Each talk features an entrepreneur and their startup story, as well as some guidance and resources for those interested in learning more about the startup process. Come and meet people others interested in life science startups, as well as members of the MBC BioLabs and Y Combinator teams who have funded over 300 bio startups between them.

Register for Series Launch: January 18, 2021, 12pm-1pm PST – Online Event



MBC BioLabs Founder Doug Crawford congratulating Irene Griswold-Prenner on running an experiment on her first day with a bottle of champaign.

Register for Series Launch: January 18, 2021, 12pm-1pm PST – Online Event



About Our Presenter

Irene Griswold-Prenner, PhD, is Founder and CEO/CSO of Nitrome Biosciences. She is a Nitrome Biosciences is a platform company developing drugs against a new family of enzymes they discovered while working at two benches at MBC BioLabs. These enzymes play a harmful role in a variety of age and inflammation dependent diseases. The therapies that Nitrome is developing will target these enzymes and potentially help slow or halt the progression of diseases such as Parkinson’s.

While the initial focus is on Parkinson’s disease, the company aims to expand its proprietary platform to include other disease indications.

She was previously a Co-founder and the CSO of Imago Pharmaceuticals. Imago, a privately held pharmaceutical company, engaged in development of drug candidates directed against JNK for fibrosis and neurodegenerative disease treatment. Imago acquired Elan Pharmaceuticals’ preclinical assets, including JNK, from which all assets were developed and partnered or sold to biotech or pharmaceuticals to continue their development.

She led iPierian’s research efforts when value creation was realized for up to $725 million from the BMS acquisition of iPierian for IPN007, the first tau therapeutic antibody to begin human testing. IPN007 was purchased by Biogen for up to $1.4 billion and is testing in Phase 2 studies for PSP and AD. IPN007 is also the first drug candidate into clinical trials where the discovery originated from an iPSC approach.

Irene worked at Elan Pharmaceuticals, contributed to Alzheimer’s disease, Parkinson’s disease and Multiple Sclerosis Programs.

She received her BA from Colorado University in Molecular, Cellular and Developmental Biology and Ph. D. from University of Chicago in Physiology and Cellular Pharmacology.

This talk will focus on Irene’s story on the origin of Nitrome, how she overcame universal skepticism to go on to achieve great success, and what inspired her to take the first steps to start her company. Irene’s story is a great example of the path we hope you too will take.

About MBC BioLabs

Slide Schedule a Tour to Learn
How MBC BioLabs Can Help
Your Company Succeed.
Learn More About MBC BioLabs

Rent a Bench. Change the World.

We’ve Helped 196 Companies Raise $4.75B In Funding.

Talk about enabling awesome.

MBC BioLabs has helped 196 companies raise an average of $24.2M, for a total of $4.75B raised! When we say we enable awesome, we mean it. MBC BioLabs gives life science innovators and entrepreneurs the facilities and equipment they need to be running experiments from day 1. Seriously. We even have a tradition of doing a champagne toast for every company that runs an experiment on its first day.

MBC BioLabs frees startups from the Catch 22 of needing funding to get data, and needing data to get funding by providing the space, the equipment, and the community. Click below to tour one of our labs!

About Y Combinator

Y Combinator provides seed funding for startups. Seed funding is the earliest stage of venture funding. It pays your expenses while you’re getting started.

Some companies may need no more than seed funding. Others will go through several rounds. There is no right answer; how much funding you need depends on the kind of company you start.

At Y Combinator, our goal is to get you through the first phase. This usually means: get you to the point where you’ve built something impressive enough to raise money on a larger scale. Then we can introduce you to later stage investors—or occasionally even acquirers.

Learn More About Y Combinator